UCCRC Research Program Four

Clinical and Experimental Therapeutics

Program Leaders:  Everett E. Vokes, MD and M. Eileen Dolan, PhD

The Clinical and Experimental Therapeutics Program is a cohesive, integrated program with 53 members representing 10 departments. The program has a long-standing focus on drug development at all phases of clinical testing and a strong pharmacogenetic component.  The types of trials range from preclinical development to investigator-initiated Phase I clinical trials, to Phase II trials in the regional Phase II network, to Phase III studies with CALGB. The scientific goals are:

• to foster interaction between basic and clinical investigators that will result in innovative and effective therapies;
• to integrate new drugs into the development of multimodality therapies for patients with advanced solid tumors; and
• to pursue a broad program of preclinical, translational, and clinical research in pharmacogenetics and pharmacology.

The program has a long-standing focus on drug development at all phases of clinical testing and a strong pharmacogenetic component. The translational nature of much of the work emanating from this program and the leadership role assumed by many program faculty in studies conducted by national clinical cooperative groups illustrates the impact of this program in developing new therapies for oncology.

Program Highlights 2008

 

 

Program 1
Cell Signaling and Gene Regulation
Program Leaders: Marsha Rosner, PhD and Suzanne Conzen, MD

Program 2
Molecular Genetics and Hematopoiesis
Program Leaders: Wendy Stock, MD and Michael Thirman, MD

Program 3
Immunology and Cancer
Program Leader: Thomas F. Gajewski, MD, PhD

Program 4
Clinical and Experimental Therapeutics
Program Leaders: Everett E. Vokes, MD and M. Eileen Dolan, PhD

Program 5
Advanced Imaging
Program Leaders: Greg Karczmar, PhD and Heber MacMahon, MD

Program 6
Cancer Risk and Prevention
Program Leaders: Brian Chiu, PhD and Andrea King, PhD